207 related articles for article (PubMed ID: 36081350)
21. Apolipoprotein L3 enhances CD8+ T cell antitumor immunity of colorectal cancer by promoting LDHA-mediated ferroptosis.
Lv Y; Tang W; Xu Y; Chang W; Zhang Z; Lin Q; Ji M; Feng Q; He G; Xu J
Int J Biol Sci; 2023; 19(4):1284-1298. PubMed ID: 36923931
[No Abstract] [Full Text] [Related]
22. Cyclin-dependent kinase 9 expression and its association with CD8
Wang J; Liu J; Tian F; Zhan Y; Kong D
Oncol Lett; 2019 Dec; 18(6):6046-6056. PubMed ID: 31788079
[TBL] [Abstract][Full Text] [Related]
23. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
24. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Tumor Cell-Intrinsic Expression of Cyclic GMP-AMP Synthase (cGAS)-Stimulator of Interferon Genes (STING) on the Infiltration of CD8
Nakajima S; Kaneta A; Okayama H; Saito K; Kikuchi T; Endo E; Matsumoto T; Fukai S; Sakuma M; Sato T; Mimura K; Saito M; Saze Z; Sakamoto W; Onozawa H; Momma T; Kono K
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345163
[TBL] [Abstract][Full Text] [Related]
26. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
27. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
30. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang C; Fakih M
Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
[TBL] [Abstract][Full Text] [Related]
31. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
32. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
33. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
[TBL] [Abstract][Full Text] [Related]
34. CCL5-deficiency enhances intratumoral infiltration of CD8
Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y
Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
Front Immunol; 2022; 13():947756. PubMed ID: 36003387
[TBL] [Abstract][Full Text] [Related]
36. Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.
Katkeviciute E; Hering L; Montalban-Arques A; Busenhart P; Schwarzfischer M; Manzini R; Conde J; Atrott K; Lang S; Rogler G; Naschberger E; Schellerer VS; Stürzl M; Rickenbacher A; Turina M; Weber A; Leibl S; Leventhal GE; Levesque M; Boyman O; Scharl M; Spalinger MR
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33001862
[TBL] [Abstract][Full Text] [Related]
37. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
Front Oncol; 2022; 12():841977. PubMed ID: 35371995
[TBL] [Abstract][Full Text] [Related]
38. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
Front Immunol; 2022; 13():965492. PubMed ID: 36389685
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.
Liu C; Xiao H; Cui L; Fang L; Han S; Ruan Y; Zhao W; Zhang Y
Front Immunol; 2022; 13():1039631. PubMed ID: 36479108
[TBL] [Abstract][Full Text] [Related]
40. Targeting m
Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
